# US 2026/0232825 A1 · Linker-drug molecule and antibody drug conjugate, preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232825 A1
- Document ID: US20260232825A1
- Status: Published application
- Kind: A1
- Application number: 19/441,753
- Filed: 2026-01-06
- Published: 2026-08-13
- Earliest claimed: 2023-07-07
- Applicants: Shanghai Escugen Biotechnology Co., Ltd.
- Inventors: Di ZENG; Chuanying XU; Weihong NIAN; Hongbin YAN; Zhuzi HE; Hongli WEI; Xintong ZHENG; Xinmin ZHANG; Feng HE; Qing ZHOU
- Web page: https://patentgrep.com/patent/US20260232825A1

## CPC

- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 5/02: containing at least one abnormal peptide link
- C07K 5/0205: {containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof}
- C07K 5/021: {containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds}
- C07K 5/06017: {and aliphatic}
- C07K 5/06052: {Val-amino acid}
- C07K 5/0815: {with the first amino acid being basic}
- C07K 5/1005: {and aliphatic}
- C07K 5/1008: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A compound represented by formula (1), or a tautomer, mesomer, racemate, enantiomer, and diastereomer thereof, or mixture form thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein the structure of formula (1) is as shown below: formula (1). According to the compound, a strong hydrophilic sulfonate inner salt and/or phosphate inner salt side chain are introduced at the position of polypeptide (VC, VA, AAA, etc.)-PAB (self-immolative group) of a linker, greatly enhancing the druggability (comprising hydrophilicity and stability) of an antibody drug conjugate corresponding to the compound, reducing the in-vivo drug clearance effect, and improving the tumor treatment effect.

## Claims

### Claim 1

A compound represented by Formula (1), or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Formula (1) has the following structural formula:
M is a spacer;
Sp is -La-Qa-;
A is selected from absent, hydrogen and alkyl;
T represents a straight or branched (C1-C8) trivalent alkyl group;
Y, Y′ and Y″ are each independently -Lb-Qb-; La and La are each independently selected from absent, alkylene, alkenylene, alkynylene, alicyclylene, heteroalicyclylene, arylene, heteroarylene and polyethylene glycol group, wherein the alkylene, alkenylene, alkynylene, alicyclylene, heteroalicyclylene, arylene, heteroarylene or polyethylene glycol group is optionally substituted;
Qa, and Qb are each independently selected from absent, —C(═O)NR—, —C(═O)O—, —OC(═O)NR—, —S(═O)2NR—, —NRC(═O)—, —OC(═O)—, —NRC(═O)O—, —NRS(═O)2—, —NRC(═O)NR—, —NHC—(═NH)NH—, —C(═O)—, —OC(═O)O—, —O—, —NR—, —S—, S(═O)2—, S(═O)—, and —Se—, wherein R is hydrogen or optionally substituted alkyl;
Z is selected from absent, hydrogen, optionally substituted alkyl and a sulfonate inner salt;
Z′, and Z″ are each independently selected from absent, hydrogen, optionally substituted alkyl, a sulfonate inner salt and a phosphate inner salt;
at least one of Z, Z′ and Z″ is a sulfonate inner salt or a phosphate inner salt;
X comprises a self-immolative unit or is absent;
D comprises a drug molecule;
i is an integer equal to or greater than 1;
h is an integer from 1 to 6; and
o, p and q are each independently an integer from 0 to 5;
preferably the Formula (1) is Formula (1-1):
wherein at least one of the i Zs is a sulfonate inner salt; or
preferably the Formula (1) is Formula (1-2):
wherein Z is a sulfonate inner salt or a phosphate inner salt; or
preferably the Formula (1) is Formula (1-3):
wherein Z″ is a sulfonate inner salt or a phosphate inner salt.

### Claim 2 (depends on 1)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 1,
wherein the Formula (1-1) is Formula (1-1-1):
wherein AA is an amino acid residue, and W is an integer equal to or greater than 1; or
the Formula (1-2) is Formula (1-2-1):
wherein AA is an amino acid residue, and W is an integer equal to or greater than 1; or
the Formula (1-3) is Formula (1-3-1):
wherein AA is an amino acid residue, and W is an integer equal to or greater than 1.

### Claim at position 3

3-7. (canceled)

### Claim 8 (depends on 1)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 1, wherein when A and Z are absent, N, Y and T form a ring to have a structural formula of:

### Claim 9 (depends on 2)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 2, wherein
the amino acid(s) is one or more selected from the group consisting of: alanine, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; or
M is selected from N3, SH, ON H2, NH2, CO2H, (alkyl)-CO—, HCO—, BrCH2, ICH2—,
or
A is hydrogen, methyl, ethyl or propyl; or
the T is any one selected from the group consisting of:
La is one, two, three or more selected from the group consisting of: alkylene, alkenylene, alkynylene, saturated or unsaturated alicyclylene with 3-10 ring carbon atoms, saturated or unsaturated heteroalicyclylene with 3-10 ring carbon atoms and 1-4 heteroatoms, arylene with 6-18 carbon atoms in one or more rings, heteroarylene with 6-18 carbon atoms and 1-4 heteroatoms in one or more rings, and polyethylene glycol group; and wherein the alkylene, alkenylene, alkynylene, alicyclylene, heteroalicyclylene, arylene, or heteroarylene is optionally substituted by a substituent; and the heteroatom is selected from nitrogen, oxygen, or sulfur; or
Lb is one, two, three or more selected from the group consisting of: alkylene, alkenylene, alkynylene, saturated or unsaturated alicyclylene with 3-10 ring carbon atoms, saturated or unsaturated heteroalicyclylene with 3-10 ring carbon atoms and 1-4 heteroatoms, arylene with 6=18 carbon atoms in one or more rings, or heteroarylene with 6-18 carbon atoms and 1-4 heteroatoms in one or more rings, and polyethylene glycol group; and wherein the alkylene alkenylene, alkynylene, alicyclylene, heteroalicyclylene, arylene, or heteroarylene is optionally substituted by a substituent; and the heteroatom is selected from nitrogen, oxygen, or sulfur; or
Qa is one, two, three or more selected from the group consisting of: —C(═O)NR—, —NR—, ═C(O═)O—, —OC(═O)NR—, —NRC(═O)—, —OC(═O)—, —NRC(═O)O—, —NRC(═O)NR—, NHC—(═NH)NH—, —C(═O)—, and —OC(═O)O—; and wherein R is selected from hydrogen, or optionally substituted C1-C6 linear or branched alkyl; or
Qb is one, two, three or more selected from the group consisting of: absent, —C(═O)NR—, —C(═O)O—, —OC(═O)NR—, —NRC(═O)—, —OC(═O)—, —NRC(═O)O—, —NRC(═O)NR—, NHC—(═NH)NH—, —C(═O)—, and —OC(═O)O—; and wherein R is selected from hydrogen, or optionally substituted C1-C6 linear or branched alkyl; or
X is selected from:
the wavy line at right side of X is connected to D;
R4 is selected from hydrogen, C1-C6 linear or branched alkyl, —(CH2CH2O)mR2, —CH2CH2NR2R3, or —CH2CH2SO2R2;
R2, and R3 are each independently selected from hydrogen, or C1-C6 linear or branched alkyl; and m is an integer greater than 1; or
the sulfonate inner salt is
the wavy line is connected to Y, Y′ or Y′″;
wherein c, d, e, f, and g are each independently an integer selected from 1, 2, 3, 4, 5 or 6; and
R6, R7, R11, R12, R13, and R14 are each independently selected from absent, hydrogen, or C1-C6 linear or branched alkyl; or
the phosphate inner salt is
wherein
a and b are each independently an integer selected from 1, 2, 3, 4, 5 or 6; and wherein
R8, R9 and R10 are each independently selected from hydrogen, or C1-C6 linear or branched alkyl; or
the D comprises a cytotoxin or immune agonist.

### Claim at position 6

10-52. (canceled)

### Claim 53 (depends on 1)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 1, wherein La is one, two, three or more selected from the group consisting of C1-C6 linear or branched alkylene, and polyethylene glycol group;
wherein the polyethylene glycol group is —(CH2CH2O)n—, —O(CH2CH2O)n—, —(CH2CH2O)nCH2—, —(CH2CH2O)nCH2CH2—, —CH2O(CH2CH2O)n—, or —CH2O(CH2CH2O)nCH2—; n is an integer equal to or greater than 1;
Qa is one, two, three or more selected from the group consisting of —C(═O)—, —NR—, —NR(C═O)—, and —(C═O)NR—; and wherein
R is selected from hydrogen, or C1-C6 linear or branched alkyl.

### Claim at position 8

54-55. (canceled)

### Claim 56 (depends on 1)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 1, wherein L is selected from C1-C6 linear or branched alkylene, C2-C6 linear or branched alkenylene, or C2-C6 linear or branched alkynylene, arylene with 6-10 carbon atoms in one or more rings, or polyethylene glycol group;
the polyethylene glycol group is one, two, three or more selected from the group consisting of: —(CH2CH2O)n—, —O(CH2CH2O)n—, —(CH2CH2O)nCH2—, —(CH2CH2O)nCH2CH2—, —CH2O(CH2CH2O)n—, and —CH2O(CH2CH2O)nCH2—; n is an integer equal to or greater than 1; the alkylene, alkenylene, or alkynylene is optionally substituted by a substituent;
Qb is one, two, three or more selected from the group consisting of absent, —C(═O)NR—, —C(═O)O—, —OC(═O)NR—, —NRC(═O)—, —OC(═O)—, —NRC(═O)O—, —NRS(═O)2—, —NRC(═O)NR—, —C(O)—, and —OC(═O)O—; and wherein R is selected from hydrogen, or optionally substituted C1-C6 linear or branched alkyl.

### Claim 57 (depends on 1)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 1,
the substituent is any one selected from the group consisting of: deuterium, tritium, halogen, amino, hydroxyl, cyano, nitro, optionally substituted alkyl, alkenyl, alkynyl, optionally substituted heterocyclyl, acyl, optionally substituted amino, optionally substituted aminoformyl, optionally substituted thioaminoformyl, optionally substituted sulfamine, optionally substituted hydroxyl, optionally substituted thioalkyl (SH), and optionally substituted silyl.

### Claim at position 11

58-59. (canceled)

### Claim 60 (depends on 1)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 1, wherein the compound is any one selected from the group consisting of:

### Claim 61

A compound represented by Formula (2), or a tautomer, enantiomner or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Formula (2) has the following structural formula:
Ab comprises an antibody or an antigen-binding fragment thereof;
M′ is a spacer;
Sp is -La-Qa-;
A is selected from absent, hydrogen or alkyl;
T represents a straight or branched (C1-C8) trivalent alkyl group;
Y, Y′ and Y″ are each independently -Lb-Qb-;
La and Lb are each independently selected from absent, alkylene, alkenylene, alkynylene, alicyclylene, heteroalicyclylene, arylene, heteroarylene or polyethylene glycol group, wherein the alkylene, alkenylene, alkynylene, alicyclylene, heteroalicyclylene, arylene, heteroarylene or polyethylene glycol group is optionally substituted by a substituent;
Qa, and Qb are each independently selected from absent, —C(═O)NR—, —C(═O)O—, —OC(═O)NR—, —S(═O)2NR—, —NRC(═O)—, —OC(═O)—, —NRC(═O)O—, —NRS(═O)2—, —NRC(═O)NR—, —NHC—(═NH)NH—, —C(═O)—, —OC(═O)O—, —O—, —NR—, —S—, S(═O)2—, S(═O)—, or —Se—; wherein R is selected from hydrogen or optionally substituted alkayl;
Z is selected from absent, hydrogen, optionally substituted alkyl or a sulfonate inner salt;
Z′ and Z″ are each independently selected from absent, hydrogen, optionally substituted alkyl, a sulfonate inner salt or a phosphate inner salt;
at least one of Z, Z′ and Z″ is a sulfonate inner salt or a phosphate inner salt;
X comprises a self-immolative unit or is absent;
D comprises a drug molecule;
i is an integer equal to or greater than 1;
h is an integer from 1 to 6;
o, p, and q are each independently an integer selected from 0-5; and
j is an integer equal to or greater than 1;
preferably the Formula (2) is Formula (2-1):
wherein at least one of the i Zs is a sulfonate inner salt; or
preferably the Formula (2) is Formula (2-2):
wherein Z″ is a sulfonate inner salt or a phosphate inner salt; or
the Formula (2) is Formula (2-3):
wherein Z″ is a sulfonate inner salt or a phosphate inner salt.

### Claim 62

(canceled)

### Claim 63 (depends on 61)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 61, wherein the Formula (2-1) is Formula (2-1-1):
wherein AA is an amino acid residue, and
W is an integer equal to or greater than 1; or
the Formula (2-2) is Formula (2-2-1):
wherein AA is an amino acid residue, and W is an integer equal to or greater than 1; or
the Formula (2-3) is Formula (2-3-1):
wherein AA is an amino acid residue, and W is an integer equal to or greater than 1.

### Claim at position 16

64-67. (canceled)

### Claim 68 (depends on 61)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 61, wherein when A and Z are absent, N, Y and T form a ring to have a structural formula of

### Claim 69 (depends on 63)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 63, wherein the amino acid(s) is one or more selected from the group consisting of: alanine, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; or
M′ is any one selected from the group consisting of:
and
* is connected to Ab or
A is hydrogen, methyl, ethyl or propyl; or
the T is any one selected from the group consisting of:
or
La is one, two, three or more selected from the group consisting of: alkylene, alkenylene, alkynylene, saturated or unsaturated alicyclylene with 3-10 ring carbon atoms, saturated or unsaturated heteroalicyclylene with 3-10 ring carbon atoms and 1-4 heteroatoms, arylene with 6-18 carbon atoms in one or more rings, heteroarylene with 6-18 carbon atoms and 1-4 heteroatoms in one or more rings, and polyethylene glycol group; and wherein the alkylene, alkenylene, alkynylene, alicyclylene, heteroalicyclylene, arylene, or heteroarylene is optionally substituted by a substituent; and the heteroatom is selected from nitrogen, oxygen, or sulfur; or
Lb is one, two, three or more selected from the group consisting of: alkylene, alkenylene, alkynylene, saturated or unsaturated alicyclylene with 3-10 ring carbon atoms, saturated or unsaturated heteroalicyclylene with 3-10 ring carbon atoms and 1-4 heteroatoms, arylene with 6-18 carbon atoms in one or more rings, or heteroarylene with 6-18 carbon atoms and 1-4 heteroatoms in one or more rings, and polyethylene glycol group; and
wherein the alkylene, alkenylene, alkynylene, alicyclylene, heteroalicyclylene, arylene, or heteroarylene is optionally substituted by a substituent; and the heteroatom is selected front nitrogen, oxygen, or sulfur; or
Qa is one, two, three or more selected from the group consisting of: —C(═O)NR—, —NR—, —C(═O)O—, —OC(═O)NR—, —NRC(═O)—, —OC(═O)—, —NRC(═O)O—, —NRC(═O)NR—, NHC—(═NH)NH—, —C(═O)—, —OC(═O)O—; and wherein R is selected from hydrogen, or optionally substituted Cr—Cs linear or branched alkyl; or
Qb is one, two, three or more selected from the group consisting of: absent, —C(═O)NR—, —C(═O)O—, —OC(═O)NR—, —NRC(═O)—, —OC(═O)—, —NRC(═O)O—, —NRC(═O)NR—, NHC—(═NH)NH—, —C(═O)—, —OC(═O)O—; and wherein R is selected from hydrogen, or optionally substituted C1-C6 linear or branched alkyl; or
X is selected from:
the wavy line at right side of X is connected to D;
R4 is selected from hydrogen, C1-C6 linear or branched alkyl, —(CH2CH2O)mR2, —CH2CH2NR2R3, or —CH2CH2SO2R2—;
R2, and R3 are each independently selected from hydrogen, or C1-C6 linear or branched alkyl; and m is an integer greater than 1; or
the sulfonate inner salt is
the wavy line is connected to Y, Y′ or Y″;
wherein c, d, e, f, and g are each independently an integer selected from 1, 2, 3, 4, 5 or 6; and
R6, R7, R11, R12, R13 and R14 are each independently selected from absent, hydrogen, C1-C6 linear or branched alkyl; or
the phosphate inner salt is
wherein
a and b are each independently an integer selected from 1, 2, 3, 4, 5 or 6; and R8, R9 and R10 are each independently selected from hydrogen or C1-C6 linear or branched alkyl; or
the D comprises a cytotoxin or immune agonist.

### Claim at position 19

70-106. (canceled)

### Claim 107 (depends on 69)

The compound, or a tautomer, enantiomner or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 69, wherein La is one, two, three or more selected from the group consisting of: C1-C6 linear or branched alkylene, and polyethylene glycol group;
the polyethylene glycol group is —(CH2CH2O)—, —O(CH2CH2O)—, —(CH2CH2O)nCH2—, —(CH2CH2O)nCH2CH2—, —CH2O(C2CH2O)n—, or —CH2O(CH2CH2O)nCH2—, n is an integer equal to or greater than 1;
Qa is one, two, three or more selected from the group consisting of: —C(═O)—, —NR(C═O)—, and —(C═O)NR—; and wherein
R is selected from hydrogen, or C1-C6 linear or branched alkyl.

### Claim at position 21

108-114. (canceled)

### Claim 115 (depends on 69)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 69, wherein La is ethylidene and/or —(CH2CH2O)4CH2CH2— or pentylidene; and
Qa is —C(═O)—, —N(CH3)—, —NH(C═O)—, —C(═O)NH— or —C(═O)—N(CH3)—.

### Claim 116 (depends on 69)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 69, wherein Lb is selected from C1-C6 linear or branched alkylene, C2-C6 linear or branched alkenylene, or C2-C6 linear or branched alkynylene, arylene with 6-10 carbon atoms in one or more rings, or polyethylene glycol group; and wherein
the polyethylene glycol group is one, two, three or more selected from the group consisting of: —(CH2CH2O)n—, —O(CH2CH2O)n—, —(CH2CH2O)nCH2—, —(CH2CH2O)nCH2CH2—, —CH2O(CH2CH2O)n—, and —CH2O(CH2CH2O)nCH2—; n is an integer equal to or greater than 1; the alkylene, alkenylene, or alkynylene is optionally substituted by a substituent;
Qb is one, two, three or more selected from the group consisting of: absent, —C(═O)NR—, —C(═O)O—, —OC(═O)NR—, —NRC(═O)—, —OC(═O)—, —NRC(═O)O—, —NRS(═O)2—, —NRC(═O)NR—, —C(═O)—, and —OC(═O)O—; and R is selected from hydrogen, or optionally substituted C1-C6 linear or branched alkyl.

### Claim 117

(canceled)

### Claim 118 (depends on 69)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 69, wherein Lb is one, two, three or more selected from the group consisting of: methylene, ethylene, n-propylidene, isopropylidene, n-butylidene, isobutylidene, sec-butylidene, tert-butylidene, and benzylidene;
Qb is one, two, three or more selected from the group consisting of: absent, —C(═O)—, —NRC(═O)—, —NRC(═O)NR—, and —C(═O)NR—; and R is hydrogen or methyl.

### Claim 119 (depends on 69)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 69, wherein the substituent is any one selected from the group consisting of: deuterium, tritium, halogen, amino, hydroxyl, cyano, nitro, optionally substituted alkyl, alkenyl, alkynyl, optionally substituted heterocyclyl, acyl, optionally substituted amino, optionally substituted aminoformyl, optionally substituted thioaminoformyl, optionally substituted sulfamine, optionally substituted hydroxyls, optionally substituted thioalkyl (SH), and optionally substituted silyl.

### Claim 120

(canceled)

### Claim 121 (depends on 69)

The compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 69, wherein the compound is any one selected from the group consisting of:

### Claim at position 29

122-131. (canceled)

### Claim 132 (depends on 69)

A pharmaceutical composition, comprising the compound, or a tautomer, enantiomer or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof according to claim 69.

### Claim at position 31

133-137. (canceled)

### Claim 138 (depends on 69)

A method for treating and/or preventing a tumor, comprising administering to a patient the compound, or a tautomer, enantiomer or diastereomer according to claim 69;
preferably, the tumor is a tumor associated with a target selected from the group consisting of: Claudin18.2, human folate receptor, HER2, HER3, TROP2, B7-H3, GPC20, CDH6, EGFR, EGFRvIII, AXL, Nectin-4, Tissue factor, TIM-1, PSMA, EpCAM, MUC1, STEAP1, GPNMB, FGF2, FOLR1, c-MET, GFR, AGS-16, Guanylyl cyclase C, Mesothelin, SLC44A4, EphA2, AGS-5, GPC-3, c-KIT, ROR1, PD-L1, CD27L, 5T4, Mucin 16, NaPi2b, STEAP, SLITRK6, ETBR, BCMA, CEACAM5, SC-16, SLC39A6, Delta-like protein3, Claudin18.2, CD19, CD20, CD22, CD30, CD33, CD37, CD45, CD56, CD66e, CD70, CD73, CD74, CD79b, CD138, CD147, CD166, CD223, MUC16, MSLN, ENPP3, SLTRK6, FGFR, LIV-1, Lewis Y, av-integrin, ASCT2, C4.4a, CA-IX, CD324, CD352, CD44v6, CD48a, CLL-1, Cripto, CS1, DPEP3, Ephrin-A2, Ephrin-A4, ETBR, FGFR2, FGFR3, FLT3, GD3, Globo H, GPC3, LAMP-1, LRRC15, Ly6E, MFI2, NOTCH3, p-cadherin, PRLR and RNF43;
preferably, the tumor is selected from the group consisting of:
esophageal cancer, gastrointestinal cancer, pancreatic cancer, thyroid cancer, colorectal cancer, kidney cancer, lung cancer (such as non-small cell lung cancer), liver cancer, stomach cancer, gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, head and neck cancer, bladder cancer, breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostatic cancer, testicular cancer, germ cell cancer, bone cancer, skin cancer, thymus cancer, bile duct cancer, gallbladder cancer, melanoma, mesothelioma, lymphoma, myeloma (such as multiple myeloma), sarcoma, glioblastoma and leukemia.
